SQZ Biotechnologies Net Income 2020-2022 | SQZ

SQZ Biotechnologies net income from 2020 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
SQZ Biotechnologies Annual Net Income
(Millions of US $)
2021 $-69
2020 $-51
2019 $-32
SQZ Biotechnologies Quarterly Net Income
(Millions of US $)
2022-09-30 $-23
2022-06-30 $-22
2022-03-31 $-21
2021-12-31 $-12
2021-09-30 $-22
2021-06-30 $-19
2021-03-31 $-15
2020-12-31 $-18
2020-09-30 $-12
2020-06-30 $-10
2020-03-31 $-11
2019-12-31
2019-09-30 $-8
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.023B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $151.446B 9.24
GSK (GSK) United Kingdom $72.652B 9.59
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.227B 19.16
Ginkgo Bioworks Holdings (DNA) United States $3.880B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Arcus Biosciences (RCUS) United States $1.620B 24.32
Biohaven (BHVN) United States $1.283B 0.00
Emergent Biosolutions (EBS) United States $0.681B 5.35
ADC Therapeutics SA (ADCT) Switzerland $0.419B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.066B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00